This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This HRASLS3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-132 amino acids from the C-terminal region of human HRASLS3.
PLA2G16
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
HRP
Applikationshinweise
For WB starting dilution is: 1:1000
For FACS starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
HRASLS3 antikoerper, HREV107 antikoerper, HRSL3 antikoerper, AdPLA antikoerper, H-REV107-1 antikoerper, HREV107-1 antikoerper, HREV107-3 antikoerper, C78643 antikoerper, Hrasls3 antikoerper, Hrev107 antikoerper, MLP-3 antikoerper, phospholipase A2 group XVI antikoerper, phospholipase A2, group XVI antikoerper, PLA2G16 antikoerper, Pla2g16 antikoerper
Hintergrund
PLA2G16 specifically catalyzes the release of fatty acids from phospholipids in adipose tissue. It also has a weak lysophospholipase activity (By similarity). Tumor suppressor that may be involved in interferon-dependent cell death.